Previous close | 67.29 |
Open | 67.50 |
Bid | 66.50 |
Ask | 67.30 |
Strike | 170.00 |
Expiry date | 2024-01-19 |
Day's range | 67.03 - 67.50 |
Contract range | N/A |
Volume | |
Open interest | 244 |
Novavax gets green light from FDA, awaits CDC recommendation for booster COVID doses.
The Serum Institute of India has received a recommendation from WHO for malaria doses using a Novavax adjuvant.
(Bloomberg) -- Novavax Inc.’s updated version of its Covid-19 shot gained US regulators’ authorization for emergency use amid a rocky rollout of competitors’ offerings.Most Read from BloombergKey Taiwan Tech Firms Helping Huawei With China Chip PlantsWhy a US Recession Is Still Likely — and Coming SoonStocks, Bonds Sell Off as Volatility Makes Return: Markets WrapAirbnb Is Fundamentally Broken, Its CEO Says. He Plans to Fix It.JPMorgan’s Dimon Predicts 3.5-Day Work Week for Next Generation Thank